The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Rationale The DSM-IV includes the specifier "generalized" to refer to social anxiety disorder (social phobia) patients if the fears include "most social situations". The focus on interventions such as the selective serotonin reuptake inhibitors (SSRIs) for generalized social anxiety disorder arguably runs the risk that inadequate treatment will be provided to patients with the non-generalized or discrete subtypes. There are, however, few data to address whether more generalized and less generalized subgroups of social anxiety disorder differ in response to medication.Objective To compare response of more generalized and less generalized social anxiety disorder to pharmacotherapy.Methods Data from three randomized placebo-controlled double-blind multicenter trials of the SSRI paroxetine in social anxiety disorder were pooled. Response on the Clinical Global Impression Global Improvement item was analyzed using logistic regression, and change in total Liebowitz Social Anxiety Score was analyzed using analysis of variance, with both models incorporating treatment (paroxetine vs placebo), subgroup (more generalized vs less generalized), demographic, and clinical variables.Results The prevalence of more generalized social anxiety disorder was higher in females than in males. However, there was no significant difference in terms of age or clinical characteristics (duration of condition, baseline pulse, mean arterial blood pressure). At treatment endpoint there were significant treatment effects (for paroxetine vs placebo), but no significant subgroup effects (for more generalized vs less generalized).Conclusions Although the current database is limited insofar as few patients with discrete social anxiety disorder would have been included, it is helpful in addressing the value of medication for patients lying on the spectrum from generalized to non-generalized and discrete social anxiety disorder. Paroxetine was effective in both more generalized and in less generalized social anxiety disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SSRIs, on the other hand, may be useful for patients with both more limited or more generalized social anxiety disorder 99 .”
From The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management (2021) · cites this paper as [99]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1976) · Medical Entomology and Zoology · Cited by 8,899
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142 · cited 1×
“National and cross-national studies of social anxiety disorder (or social phobia) have documented that this disorder is highly prevalent in many countries (with prevalences ranging, for example, from 2.6 to 13.3% in the United States), that it has a chronic course when untreated, and that it is associated with signifi…”
BackgroundInfluentialPsychometric properties of the Liebowitz Social Anxiety Scale
HEIMBERG, R. G., HORNER, K. J., JUSTER, H. R., SAFREN, S. A., BROWN, E. J., SCHNEIER, F. R., & LIEBOWITZ, M. R. (1999) · Psychological Medicine · doi:10.1017/s0033291798007879 · Cited by 968 · cited 2×
“As part of the post hoc analysis of the data, two definitions of more generalized and less generalized social anxiety disorder were devised using the baseline LSAS, a 24-item scale in which fear/anxiety and avoidance associated with different social situations are each rated on a 4-point scale (absent, mild, moderate,…”
MethodMcDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
Functional impairment in social phobia.
Schneier, F. R., Heckelman, L., Garfinkel, R. S., Campeas, R. B., Fallon, B. A., Gitow, A., Street, L. L., Bene, D. D., & Liebowitz, M. R. (1994) · PubMed · Cited by 534
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
Social Phobia Subtypes in the National Comorbidity Survey
Kessler, R. C., Stein, M. B., & Berglund, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.613 · Cited by 398
Self-citationSocial phobia: A comparison of specific and generalized subtypes and avoidant personality disorder.
Turner, S. M., Beidel, D. C., & Townsley, R. M. (1992) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.101.2.326 · Cited by 282 · cited 1×
“Further understanding of the heterogeneity of social anxiety disorder (Holt et al. 1992; Turner et al. 1992 ) may be useful for predicting response to pharmacotherapy.”
Background
Cited by
Blomstrom-Lundqvist (2003) · doi:10.1161/01.cir.0000091380.04100.84 · Cited by 955
Blomström-Lundqvist, C., Scheinman, M. M., Aliot, E. M., Alpert, J. S., Calkins, H., Camm, A. J., Campbell, W. B., Haines, D. E., Kuck, K. H., Lerman, B. B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.013 · Cited by 689
BlomstromLundqvist, C. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.08.002 · Cited by 263
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Self-citationPigott, T. A. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00040-6 · Cited by 205
Anxiety disorders in women: does gender matter to treatment?
Kinrys, G., & Wygant, L. E. (2005) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462005000600003 · Cited by 102
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.190 · Cited by 160
Benzodiazepines: More Behavioural Addiction than Dependence
de las Cuevas, C., Sanz, E., & de la Fuente, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1376-8 · Cited by 113
Psychopharmacology of anxiety disorders
Cassano, G. B., Rossi, N. B., & Pini, S. (2002) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2002.4.3/gcassano · Cited by 63
Subtyping social anxiety disorder in developed and developing countries
Stein, D. J., Ruscio, A. M., Lee, S., Petukhova, M., Alonso, J., Andrade, L. H. S. G., Benjet, C., Bromet, E., Demyttenaere, K., Florescu, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20639 · Cited by 65
“[20,21] Such findings raise questions about the value of the generalized versus non-generalized distinction.”
BackgroundSelf-citationSocial Anxiety Disorder: Associated Conditions and Therapeutic Approaches
Alomari, N. A., Bedaiwi, S. K., Ghasib, A. M., Kabbarah, A. J., Alnefaie, S. A., Hariri, N., Altammar, M. A., Fadhel, A. M., & Altowairqi, F. M. (2022) · Cureus · doi:10.7759/cureus.32687 · Cited by 77
“transmission of messages between neurons [60].”
Stein, D. J., Cameron, A., Amrein, R., & Montgomery, S. A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200207000-00002 · Cited by 65
“However, a recent post-hoc analysis of patients with more generalized and less generalized SAD indicated that the SSRI, paroxetine, was useful in both groups (Stein et al., 2001).”
BackgroundSelf-citationStein, D. J., Craske, M. G., Rothbaum, B. O., Chamberlain, S. R., Fineberg, N. A., Choi, K. W., de Jonge, P., Baldwin, D. S., & Maj, M. (2021) · World Psychiatry · doi:10.1002/wps.20919 · Cited by 60
Self-citationDefining anxious depression: going beyond comorbidity
Silverstone, P. H., & von Studnitz, E. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304801006 · Cited by 57
Stein, D. J., Kasper, S., Andersen, E. W., Nil, R., & Lader, M. (2004) · Depression and Anxiety · doi:10.1002/da.20043 · Cited by 47
“This is consistent with previous work demonstrating that both more generalized and less generalized SAD respond to treatment with an SSRI [Stein et al., 2001].”
ResultSelf-citationSinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven?
Yusuf, S., & Camm, A. J. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800202 · Cited by 48
“As an interim measure, ,-blockers can be very useful and effective in patients in various settings, including the management of emotional stress and other anxiety related disorders (46-54), after acute myocardial infarction (55,56),”
BackgroundSocial Anxiety Disorder: Current Treatment Recommendations
Muller, J. E., Koen, L., Seedat, S., & Stein, D. J. (2005) · CNS Drugs · doi:10.2165/00023210-200519050-00002 · Cited by 46
Self-citationKaminer, D., & Stein, D. J. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029902 · Cited by 38
“Furthermore, a study of pindolol as an augmentation strategy in treatment-refractory SAD did not demonstrate efficacy (Stein et al. 2001c).”
InfluentialSelf-citationAn Open Clinical Trial of Reboxetine in the Treatment of Social Phobia
Atmaca, M., Tezcan, E., & Kuloğlu, M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085419.74359.a4 · Cited by 37
Deciphering the sinus tachycardias
Yusuf, S., & Camm, A. J. (2005) · Clinical Cardiology · doi:10.1002/clc.4960280603 · Cited by 35
A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder
Stein, D. J., Baldwin, D. S., Bandelow, B., Blanco, C., Fontenelle, L. F., Lee, S., Matsunaga, H., Osser, D. N., Stein, M. B., & Ameringen, M. V. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0140-8 · Cited by 34
Self-citationde Vries, Y. A., Roest, A. M., Burgerhof, J. G. M., & de Jonge, P. (2018) · Depression and Anxiety · doi:10.1002/da.22737 · Cited by 34
Admixture analysis of the diagnostic subtypes of social anxiety disorder: Implications for the DSM-V
Aderka, I. M., Nickerson, A., & Hofmann, S. G. (2011) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2011.10.012 · Cited by 30
Dazzi, L., Seu, E., Cherchi, G., & Biggio, G. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.11.003 · Cited by 29
Predictors of pharmacotherapy response in anxiety disorders
Denys, D. A. J. P., & de Geus, F. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0078-4 · Cited by 25
“Should generalized and nongeneralized forms of SAD be treated the same way? Stein et al. [ 33 ,34] pooled data from three paroxetine trials and found that paroxetine was equally effective in generalized and nongeneralized SAD, but responders were treated significantly longer compared with nonresponders.”
BackgroundResultDazzi, L., Seu, E., Cherchi, G., & Biggio, G. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02130-7 · Cited by 24
Borella, A., Sumangali, R., Ko, J., & Whitaker‐Azmitia, P. M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00373-x · Cited by 23
Neurobiologie et pharmacothérapie de la phobie sociale
Aouizerate, B., Martin‐Guehl, C., & Tignol, J.-P. (2004) · L Encéphale · doi:10.1016/s0013-7006(04)95442-5 · Cited by 22
Stein, D. J., Andersen, E. W., & LADER, M. H. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.05.004 · Cited by 18
Self-citationRecent Insight Into the Subtypes of Social Anxiety Disorder
D’Avanzato, C., & Dalrymple, K. L. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0688-z · Cited by 17
The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
Masand, P. S., & Gupta, S. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.5.485 · Cited by 15
“1 Paroxetine Denoted as an effective treatment for a vast array of anxiety disorders including panic disorder, OCD, PTSD and SAD, paroxetine and paroxetine CR are now also indicated as pharmacotherapeutic agents for GAD [1,25].”
BackgroundJohnson, S. B., & Anderson, P. L. (2016) · Anxiety Stress & Coping · doi:10.1080/10615806.2016.1138289 · Cited by 14
Social Anxiety Disorder - A Review of Pharmacological Treatments
Robinson, H., & Hood, S. D. (2007) · Current Psychiatry Reviews · doi:10.2174/157340007780599069 · Cited by 14
Differentiating the subtypes of social anxiety disorder
Dalrymple, K. L., & D’Avanzato, C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.853446 · Cited by 12
Alpert, J. S., Antman, E. M., Smith, S. C., Faxon, D. P., Fuster, V., Gibbons, R. J., Gregoratos, G., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., et al. (2003) · Cited by 3
Shah, T. (2015) · Pepperdine Digital Commons (Pepperdine University) · Cited by 2
Bögels, S. M., & Stein, M. B. (2008) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890427750.lg03 · Cited by 2
Self-citationHerpertz, S. C. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_50 · Cited by 2
Kapfhammer, H. (2008) · Springer eBooks · doi:10.1007/978-3-540-33129-2_58 · Cited by 1
Актуальные тенденции в терапии тревожных расстройств
Ладыженский, М. Я., Городничев, А. В., & Костюкова, Е. Г. (2014) · Современная терапия психических расстройств · Cited by 1
Kapfhammer, H. (2003) · Springer eBooks · doi:10.1007/3-540-27386-7_52
Stein, D. J. (2002) · CRC Press eBooks · doi:10.3109/9780203639740-10
Self-citationHerpertz, S. C. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_85
Metadata
- Authors
- Stein, D., Stein, M., Goodwin, W., Kumar, R., & Hunter, B.
- Affiliations
- Stellenbosch University (ZA)
- University of California San Diego (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Venue
- Psychopharmacology
- Published
- 2001-11-01
- Volume
- 158
- Issue
- 3
- Pages
- 267-272
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2065666574
- Cited by
- 39
- References
- 31
- Citations by year
- 2022: 1 · 2021: 1 · 2018: 1 · 2016: 2 · 2013: 1
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- paroxetine, social anxiety disorder, generalized social anxiety, selective serotonin reuptake inhibitors, pharmacotherapy response, Liebowitz Social Anxiety Scale, Clinical Global Impression Scale
- MeSH terms
- Adult, Analysis of Variance, Anxiety Disorders, Double-Blind Method, Female, Humans, Male, Middle Aged, Confidence Intervals, Logistic Models, Odds Ratio, Selective Serotonin Reuptake Inhibitors, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.